European Urology Oncology
Издатель: Elsevier · ISSN 2588-9311 · 83 статей
- Individual Patient Data Validation of the EAU Definitions of BCG Failure in Patients with Non–muscle-invasive Urothelial Carcinoma of the Bladder: An International Multicenter Retrospective Study
- AI-MIRACLE: Artificial Intelligence and MultIpaRAmetric MRI Predict CLinical OutcomEs to Neoadjuvant Immunotherapy in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy
- EZH2 Inhibition Remodels Cell States and Enhances EGFRi Sensitization in Bladder Cancer
- Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study
- Endoscopic Kidney-sparing Surgery for Upper Tract Urothelial Carcinoma: Long-term Oncological and Functional Outcomes from a Large Single-center Cohort
- VI-RADS Score Performance in the Post-TURBT Setting: Exploring the Need for Modification
- Adjusted Comparison of First-line Enfortumab Vedotin Plus Pembrolizumab Versus Platinum-based Chemotherapy ± Avelumab Maintenance for the Treatment of Locally Advanced/Metastatic Urothelial Carcinoma
- Predicting the Development of BCG-unresponsive Disease Among Patients with High-grade Non–muscle-invasive Bladder Cancer: An International Multicenter Analysis
- Beyond Clear Cell: Rethinking Postoperative Surveillance for Non-clear Cell Renal Cell Carcinoma Subtypes
- A Systematic Review of Intracavitary Therapies for Upper Tract Urothelial Carcinoma
- FGFR3 Testing in Urothelial Carcinoma: An Expert Commentary on Best Practices From Patient Identification to Result Reporting
- Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making
- Study Protocol of OLIGOPELVIS 2–GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer
- Agentic AI for Prostate Cancer: A Vision for Multimodal Clinical Intelligence
- Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Real-world Data from a National Early Access Program Registry
- Validation of an AI-based Histologic Prognostic Biomarker in Patients with Non–muscle-invasive Bladder Cancer Using the Prospective Swedish National Register of Urinary Bladder Cancer
- Re: Andrea Necchi, Félix Guerrero-Ramos, Paul L. Crispen, et al. Gemcitabine Intravesical System plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Patients with MIBC: Primary Analysis and Biomarker Results of SunRISe-4. J Clin Oncol. In press. https://doi.org/10.1200/JCO-25-02382
- Re: Jeremy Y. Teoh, Francesco M. Bracco, Julius H. Wong, et al. A Novel Transurethral Robotic Platform for Performing En Bloc Resection of Bladder Tumour: Results from the First Phase of the VIABLE Trial. Eur Urol Oncol. 2026;9;111–115. https://doi.org/10.1016/j.euo.2025.11.005: Robotics Is Not Important Because It Is Robotic
- Reply to Selcuk Guven, Selim Soyturk, and Thomas Herrmann’s Letter to the Editor re: Jeremy Y. Teoh, Francesco M. Bracco, Julius H. Wong, et al. A Novel Transurethral Robotic Platform for Performing En Bloc Resection of Bladder Tumour: Results from the First Phase of the VIABLE Trial. Eur Urol Oncol. 2026;9:111–115. https://doi.org/10.1016/j.euo.2025.11.005: My Vision for the Novel Transurethral Robotic Platform.
- Re: Develtere D, Devos G. Metformin in prostate cancer: A negative repurposing story across the disease continuum. Urol Oncol 2026. https://doi.org/10.1016/j.euo.2026.04.014.
- Reply to Cameron E. Alexander, Ashwin Sachdeva, and Noel W. Clarke’s Letter to Editor Re: Develtere D, Devos G. Metformin in prostate cancer: A negative repurposing story across the disease continuum. Urol Oncol 2026. https://doi.org/10.1016/j.euo.2026.04.014.
- Re: Martino Pedrani, Alberto De Giorgi, Andrea Gallina, et al. When Patients Refuse Radical Cystectomy: Integrating Trimodality Therapy in the Perioperative ICI/ADC Era. Eur Urol Oncol. 2026;9:743–745. http://dx.doi.org/10.1016/j.euo.2026.04.008
- Reply to Kelly M. de Ligt, Sarah P. Psutka, and Laura S. Mertens’s Letter to the Editor Re: Martino Pedrani, Alberto De Giorgi, Andrea Gallina, et al. When Patients Refuse Radical Cystectomy: Integrating Trimodality Therapy in the Perioperative ICI/ADC Era. Eur Urol Oncol. 2026;9:743–745. http://dx.doi.org/10.1016/j.euo.2026.04.008
- Re: Roberto Contieri, Marco Paciotti, Alessandro Uleri, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non–muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol 2026;9:404–12: Pathological Restaging and Omission of Second TURBT in T1 NMIBC
- Reply to Yue Chang’s Letter to the Editor re: Contieri R, Paciotti M, Uleri A, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non–muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe trial. Eur Urol Oncol 2026;9:404–12
- Individualized Oncologic Surveillance After Radical Prostatectomy for Localized Prostate Cancer
- Adjuvant Pembrolizumab in Clear Cell Renal Cell Carcinoma: Eligibility Is Only the Beginning
- Rethinking the 3-cm Rule: Toward Biology-guided Management of Sporadic Bilateral Multifocal Papillary Renal Cell Carcinoma
- Natural History After Likely Cure Versus Recurrence After Prostate Radiotherapy (RAPTOR)
- Editorial Board